Loss of Class III β-Tubulin Induced by Histone Deacetylation Is Associated with Chemosensitivity to Paclitaxel in Malignant Melanoma Cells

被引:43
作者
Akasaka, Kiyomi [1 ,2 ]
Maesawa, Chihaya [1 ]
Shibazaki, Masahiko [1 ]
Maeda, Fumihiko [2 ]
Takahashi, Kazuhiro [2 ]
Akasaka, Toshihide [2 ]
Masuda, Tomoyuki [1 ]
机构
[1] Iwate Med Univ, Dept Pathol, Sch Med, Morioka, Iwate 0208505, Japan
[2] Iwate Med Univ, Dept Dermatol, Sch Med, Morioka, Iwate 0208505, Japan
关键词
COOPERATIVE ONCOLOGY GROUP; OVARIAN-CANCER PATIENTS; METASTATIC MELANOMA; PHASE-II; PREDICTS RESPONSE; 2ND-LINE THERAPY; IN-VITRO; COMBINATION; TRIAL; EXPRESSION;
D O I
10.1038/jid.2008.406
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Overexpression of class III beta-tubulin (TUBB3) is an important mechanism of taxane resistance. Using 7 melanoma cell lines, 2 normal neonatal human epidermal melanocyte (NHEM) cultures, and 49 primary melanomas, we investigated TUBB3 expression, its relationship to chemosensitivity to taxane derivatives, and the epigenetic mechanism controlling TUBB3 gene expression. Normal melanocytes in vitro and in vivo strongly expressed TUBB3 protein. NHEMs exhibited marked chemoresistance to paclitaxel-induced apoptosis. A subset (10 of 49, 20%) of primary malignant melanomas was TUBB3 negative. The incidence of TUBB3-negative melanomas increased with stage of progression. TUBB3 protein expression varied among cell lines; one (HMV-I) of the seven cell lines exhibited an extremely low endogenous level. TUBB3 protein expression correlated well with chemosensitivity to paclitaxel-induced apoptosis (P < 0.05). Treatment with a histone deacetylase (HDAC) inhibitor restored TUBB3 expression in HMV-I. Chromatin immunoprecipitation assays revealed that histones H3 and H4 were hypoacetylated at the TUBB3 gene in HMV-I as compared with a TUBB3-overexpressing cell type (HMV-II). Treatment with the HDAC inhibitor induced gain of histone acetylation only in HMV-I. These results suggest that loss of TUBB3 protein may be induced by histone deacetylation in a subset of malignant melanomas, and may be associated with chemosensitivity to taxane. Journal of Investigative Dermatology (2009) 129, 1516-1526; doi:10.1038/jid.2008.406; published online 1 January 2009
引用
收藏
页码:1516 / 1526
页数:11
相关论文
共 37 条
[1]   Docetaxel in combination with dacarbazine in patients with advanced melanoma [J].
Bafaloukos, D ;
Aravantinos, G ;
Fountzilas, G ;
Stathopoulos, G ;
Gogas, H ;
Samonis, G ;
Briasoulis, E ;
Mylonakis, N ;
Skarlos, DV ;
Kosmidis, P .
ONCOLOGY, 2002, 63 (04) :333-337
[2]   Temozolomide in combination with docetaxel in patients with advanced melanoma: A phase II study of the Hellenic Cooperative Oncology Group [J].
Bafaloukos, D ;
Gogas, H ;
Georgoulias, V ;
Briassoulis, E ;
Fountzilas, G ;
Samantas, E ;
Kalofonos, C ;
Skarlos, D ;
Karabelis, A ;
Kosmidis, P .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (02) :420-425
[3]   Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma [J].
Balch, CM ;
Buzaid, AC ;
Soong, SJ ;
Atkins, MB ;
Cascinelli, N ;
Coit, DG ;
Fleming, ID ;
Gershenwald, JE ;
Houghton, A ;
Kirkwood, JM ;
McMasters, KM ;
Mihm, MF ;
Morton, DL ;
Reintgen, DS ;
Ross, MI ;
Sober, A ;
Thompson, JA ;
Thompson, JF .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3635-3648
[4]   REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis [J].
Ballas, N ;
Grunseich, C ;
Lu, DD ;
Speh, JC ;
Mandel, G .
CELL, 2005, 121 (04) :645-657
[5]   Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling [J].
Deroanne, CF ;
Bonjean, K ;
Servotte, S ;
Devy, L ;
Colige, A ;
Clausse, N ;
Blacher, S ;
Verdin, E ;
Foidart, JM ;
Nusgens, BV ;
Castronovo, V .
ONCOGENE, 2002, 21 (03) :427-436
[6]   Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes [J].
Derry, WB ;
Wilson, L ;
Khan, IA ;
Luduena, RF ;
Jordan, MA .
BIOCHEMISTRY, 1997, 36 (12) :3554-3562
[7]   Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials [J].
Eigentler, TK ;
Caroli, UM ;
Radny, P ;
Garbe, C .
LANCET ONCOLOGY, 2003, 4 (12) :748-759
[8]   Class III β-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients [J].
Ferrandina, G ;
Zannoni, GF ;
Martinelli, E ;
Paglia, A ;
Gallotta, V ;
Mozzetti, S ;
Scambia, G ;
Ferlini, C .
CLINICAL CANCER RESEARCH, 2006, 12 (09) :2774-2779
[9]   Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer [J].
Fraga, MF ;
Ballestar, E ;
Villar-Garea, A ;
Boix-Chornet, M ;
Espada, J ;
Schotta, G ;
Bonaldi, T ;
Haydon, C ;
Ropero, S ;
Petrie, K ;
Iyer, NG ;
Pérez-Rosado, A ;
Calvo, E ;
Lopez, JA ;
Cano, A ;
Calasanz, MJ ;
Colomer, D ;
Piris, MA ;
Ahn, N ;
Imhof, A ;
Caldas, C ;
Jenuwein, T ;
Esteller, M .
NATURE GENETICS, 2005, 37 (04) :391-400
[10]   Histone deacetylases and cancer [J].
Glozak, M. A. ;
Seto, E. .
ONCOGENE, 2007, 26 (37) :5420-5432